Several drug treatments for COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are approved for use in Canada. This systematic review evaluated the efficacy, effectiveness, and safety of nirmatrelvir-ritonavir in adults with SARS-CoV-2 infection who are considered high risk but are not hospitalized. We also characterized which patients are most likely to benefit from treatment with nirmatrelvir-ritonavir.
| Call for patient/clinician input open | 03-Aug-23 |
|---|---|
| Call for patient/clinician input closed | 25-Sep-23 |
| Clarification: - Patient input submission received from the Gastrointestinal Society, Lung Health Foundation, Save Your Skin Foundation and Sickle Cell Awareness Group of Ontario | |
| Submission received | 15-Sep-23 |
| Submission accepted | 29-Sep-23 |
| Review initiated | 03-Oct-23 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 07-Nov-23 |
| Deadline for sponsors comments | 14-Nov-23 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | 08-Dec-23 |
| Expert committee meeting (initial) | 20-Dec-23 |
| Draft recommendation issued to sponsor | 09-Jan-24 |
| Draft recommendation posted for stakeholder feedback | 18-Jan-24 |
| End of feedback period | 02-Feb-24 |
| Clarification: - Reconsideration: major revisions requested by sponsor | |
| Expert committee meeting | 27-Mar-24 |
| Final recommendation issued to sponsor and drug plans | 11-Apr-24 |
| Final recommendation posted | 30-Apr-24 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | 25-Apr-24 |
| Canada's Drug Agency review report(s) posted | 09-Jul-24 |
